Triple

T1172161
Position Surface form Disambiguated ID Type / Status
Subject Vumerity E24937 entity
Predicate hasGenericName P23148 FINISHED
Object diroximel fumarate
Diroximel fumarate is an oral disease-modifying drug used to treat relapsing forms of multiple sclerosis by modulating the immune response.
 E24937 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: diroximel fumarate | Statement: [Vumerity, hasGenericName, diroximel fumarate]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: diroximel fumarate
Context triple: [Vumerity, hasGenericName, diroximel fumarate]
  • A. Darzalex
    Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
  • B. Fremulon
    Fremulon is a television production company founded by Michael Schur, best known for producing acclaimed comedy series such as Brooklyn Nine-Nine.
  • C. Vumerity
    Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
  • D. Versonnex
    Versonnex is a small commune in the Ain department of eastern France, located near the Swiss border in the Pays de Gex region.
  • E. Leqembi
    Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: diroximel fumarate
Triple: [Vumerity, hasGenericName, diroximel fumarate]
Generated description
Diroximel fumarate is an oral disease-modifying drug used to treat relapsing forms of multiple sclerosis by modulating the immune response.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: diroximel fumarate
Target entity description: Diroximel fumarate is an oral disease-modifying drug used to treat relapsing forms of multiple sclerosis by modulating the immune response.
  • A. Darzalex
    Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
  • B. Fremulon
    Fremulon is a television production company founded by Michael Schur, best known for producing acclaimed comedy series such as Brooklyn Nine-Nine.
  • C. Vumerity chosen
    Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
  • D. Versonnex
    Versonnex is a small commune in the Ain department of eastern France, located near the Swiss border in the Pays de Gex region.
  • E. Leqembi
    Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
  • F. None of above.

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a494082a7c819095004f423f294a64 completed March 1, 2026, 7:31 p.m.
NER Named-entity recognition batch_69a4bceb3f188190b8b767380fe5986f completed March 1, 2026, 10:25 p.m.
NED1 Entity disambiguation (via context triple) batch_69ac66879aec819098293c440a0e09a6 completed March 7, 2026, 5:55 p.m.
NEDg Description generation batch_69ac66fd58308190bb4cb09581d4a8de completed March 7, 2026, 5:57 p.m.
NED2 Entity disambiguation (via description) batch_69ac677e147081909d9f64884c443f82 completed March 7, 2026, 5:59 p.m.
Created at: March 1, 2026, 7:45 p.m.